ASk Questions in GYnecologic Oncology (ASQ-GYO) for Gynecologic Cancers

This study is testing a tool called the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List. This list is designed to help patients with gynecologic cancers (like ovarian, endometrial, cervical, vulvar, or vaginal cancer) ask more questions during their first visit with a gynecologic oncologist. The goal is to see if using this list helps you feel more confident, less stressed, trust your doctor more, and understand your condition better compared to standard care. About 70 people will join this study. You can participate if you are 18 or older, understand English, and have a confirmed or suspected gynecologic cancer diagnosis. The study will measure how your confidence changes before and after your doctor's visit.

Study design: This is an interventional study where participants are randomly assigned to either receive the ASQ-GYO Question Prompt List or standard care. About 70 participants are planned for this study.
What's involved: You will complete a survey before your new patient appointment and another survey after your appointment. If you are in the group receiving the ASQ-GYO QPL, you will get this list before your visit.
Compensation: Not stated in the trial record.
Follow-up: You will complete a post-visit survey within one week after your appointment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Completed

NAAges 18+InterventionalHealth services

Ira Winer

~68 participants

Updated 2026-08-20 on ClinicalTrials.gov

What's tested:Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in pre- and post-visit self-efficacy scores and compared by trial group

Measured over All participants will complete the PEPPI instrument twice: within 2 weeks of their first visit and again within 1 week after the visit.

Conditions

Ovarian Cancer

Endometrial Cancer

Cervical Cancer

Vulvar Cancer

Vaginal Cancer

Gestational Trophoblastic Disease

Where it's being run

1 sites across 1 states

Michigan1

Study leadership

Ira Winer, MD PhD · PRINCIPAL_INVESTIGATOR · Barbara Ann Karmanos Cancer Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

18 years of age

Understands spoken and written English

Able to consent to study participation

Biopsy confirmed gynecologic cancer diagnosis (ovarian, endometrial, cervical, vulvar, or vaginal cancer or Gestational Trophoblastic Disease) OR have imaging and/or laboratory findings highly concerning for a cancer diagnosis and have not seen a Gynecologic Oncologist

Exclusion

pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)

History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis

Previous treatment discussion with a Gynecologic Oncologist

What this trial measures

Change in pre- and post-visit self-efficacy scores and compared by trial groupAll participants will complete the PEPPI instrument twice: within 2 weeks of their first visit and again within 1 week after the visit.
The Perceived Efficacy in Patient-Provider Interactions (PEPPI) instrument is a validated, 20-item, 5-point Likert scale tool designed to measure patient's self-efficacy in obtaining medical information and attention to their medical concerns from physicians.

Trialytics